Following the 1990's Human Genome Project, Scott was among the first to recognize that harnessing genomic science for the benefit of individuals, rather than for large drug companies, could amplify medical efficacy and also slash costs. Genomic Health uses genetic data to show the potential efficacy of therapies, such as chemotherapy, on breast cancer patients. It has ongoing research in colon, prostate, renal-cell and lung cancers. Funded by Brooke Byers.

"It's embarrassingly easy to see the future. The difficulty is always in the execution. It's shocking how much money we spend without understanding the underlying mechanisms of a disease. By 2012, we’ll spend $80 billion annually on oncology. Yet across oncology, drugs work only 25% of the time, so $60 billion will be wasted! We also know that tens of thousands of early-stage breast cancer patients undergo chemo each year, even though chemo is beneficial in only four percent of all cases. By identifying which patients will benefit from the treatment, we can optimize chemotherapy and cut unnecessary spending. That's a market we want to go after."